Table 1.
Studies assessing the outcome of HAI
| Author | Year | Country | Patients, n | Treatment (HAI) | OS | Response rate, % | Complete resection, % | Study design |
|---|---|---|---|---|---|---|---|---|
| Focan et al. [39] 1999 | 1999 | Belgium | 56 | FUDR + SCT 5-FU with different infusion rates | n.a | 38–48 | 22–27 | RCT |
| Carnaghi et al. [40] 2007 | 2007 | Italy | 39 | 5-FU + SCT oxaliplatin and folinic acid | 21 months | 41 | 21 | Single-arm phase II |
| Boige et al. [42] 2008 | 2008 | France | 44 | Oxaliplatin + SCT 5-FU and leucovorin | 16 months | 87 | 18 | Prospective |
| Kemeny et al. [41] 2009 | 2009 | US | 49 | Floxuridine and dexamethasone + SCT oxaliplatin and irinotecan | 39.8 months | 92 | 47 | Phase I |
| D’Angelica et al. [35] 2015 | 2015 | US | 49 | FUDR + SCT depending on history + bevacizumab | 38 months | 76 | 47 | Single-arm phase II |
| Levi et al. [37] 2016 | 2016 | France | 64 | Irinotecan, oxaliplatin, 5-FU + SCT cetuximab | 25.5 months | 41 | 30 | Single-arm phase II |
| Pak et al. [36] 2018 | 2018 | US | 64 | FUDR + SCT depending on history + bevacizumab | 38 months | 73 | 52 | Single-arm phase II |
HAI, hepatic arterial infusion chemotherapy; SCT, systemic chemotherapy; US, United States; FUDR, fluorodeoxyuridine, 5-FU, 5-FU, n.a. not applicable.